Medical Billing / RCM | Laboratory
If there’s one frustration nearly every healthcare organization shares in 2026, it’s this:
Medical Billing / RCM | Laboratory
For years, patient financial engagement was treated as a collections problem. In 2026, that framing is officially outdated.
The Importance of Patient Engagement: Why They - And You - Need It
Learn why patient engagement is a necessity and how you can master it within your practice.
Medical Billing / RCM | Laboratory
Laboratory revenue cycle management has never been simple — but in 2026, it has become structurally harder.
Medical Billing / RCM | Laboratory
Why Accounts Receivable are the Lifeline of Every Laboratory For most laboratories, the biggest financial challenge isn’t the number of tests performed; it’s the number of claims still sitting unpaid.
Medical Billing / RCM | Laboratory
Why Laboratory RCM Is the New Profit Center Laboratories sit at the crossroads of precision science and complex finance. Every test performed represents both a clinical outcome and a potential reimbursement challenge. Between payer policy changes, strict documentation rules, and fluctuating volumes, laboratories often find their financial health limited not by test quality, but by their billing performance.
Medical Billing / RCM | Laboratory
Why Laboratory Revenue Cycles Are Harder Than Ever For laboratories, billing and reimbursement have always been complex. But in 2026, the landscape is tougher than ever with payers tightening rules, denials rising, and the costs of managing claims climbing.
Medical Billing / RCM | Laboratory
For most laboratories doing around $2 million + a year in collections, revenue cycle management (RCM) isn’t just “operations” – it’s a strategic decision with real financial consequences. With new mandates, billing pressure from payers, and now shifting legislation, lab leaders have to ask: Is our billing setup ready for 2026?
A Year That’s Testing Every Lab’s Financial Model Halfway through 2025, many diagnostic and clinical laboratories are facing a strange paradox. Test volumes remain healthy—or even rising—yet revenue is trending downward. This gap isn’t just frustrating; it’s a warning sign that familiar revenue-cycle levers no longer work in today’s reimbursement environment.
The Clock Is Already Ticking The next round of PAMA reimbursement cuts takes effect in 2026, but the data that determines those rates is being collected throughout 2025. That means the decisions you make this year—how you map payers, report rates, and validate contracts—will directly shape your revenue through 2029.